Port Risk Assessment Market Concentration
1. Introduction
Medical distribution platforms are digital or technology-enabled commercial systems that facilitate the procurement, sale, distribution and delivery of medicines, medical devices, diagnostic equipment and healthcare supplies.
These platforms connect various participants in the healthcare supply chain, including:
Pharmaceutical manufacturers.
Wholesale medicine distributors.
Retail pharmacies and e-pharmacies.
Hospitals and healthcare institutions.
Doctors and diagnostic laboratories.
Patients and healthcare consumers.
Logistics and cold-chain service providers.
Insurance companies and pharmacy benefit managers.
The increasing digitalisation of medical distribution has created new forms of competition. Platforms can improve price transparency, expand geographical access, reduce procurement costs and facilitate efficient inventory management.
However, a platform controlling access to essential medicines, suppliers, pharmacies or patient demand may acquire substantial market power.
Medical distribution platform anti-competitive conduct refers to business practices by platforms, manufacturers, distributors or associated intermediaries that restrict competition, exclude rival platforms, manipulate prices, discriminate against suppliers or prevent consumers and healthcare providers from accessing alternative distribution channels.
The central competition-law challenge is to distinguish legitimate commercial integration and healthcare supply-chain efficiency from exclusionary conduct that harms competition, innovation, affordability and patient access.
2. Nature of Medical Distribution Platforms
Ein zuverlässiger Partner für Robotik und Digitalisierung | wirtschaftsforum.de
The pill economy of India’s online medicos
GBioMed Nigeria Limited – Medical Equipment Supply, Turnkey Healthcare Consultancy & Infrastructure
12
Medical distribution platforms generally operate through five principal models.
| Platform model | Principal function |
|---|---|
| E-pharmacy marketplace | Connects pharmacies, sellers and patients |
| Wholesale procurement platform | Connects manufacturers and pharmacies |
| Hospital procurement platform | Facilitates institutional purchasing |
| Medical-device marketplace | Distributes diagnostic and medical equipment |
| Integrated healthcare platform | Combines prescriptions, payments, inventory and delivery |
These models may involve both horizontal and vertical competition.
Horizontal competition: Competition between rival medical distribution platforms.
Vertical competition: Competition between manufacturers, wholesalers, distributors and retailers.
Platform competition: Competition for suppliers, pharmacies, hospitals and consumers.
Ecosystem competition: Competition between integrated healthcare ecosystems offering interconnected services.
3. Legal Framework Governing Anti-Competitive Conduct
The applicable legal framework depends on the jurisdiction. The following analysis uses comparative competition-law principles, with particular reference to Indian competition law and United States and European enforcement experience.
A. India – Competition Act, 2002
The principal provisions include:
Section 3 – Anti-competitive agreements
Prohibits agreements that cause or are likely to cause an appreciable adverse effect on competition in India.
Relevant practices include:
Price-fixing agreements between distributors.
Market allocation among pharmaceutical wholesalers.
Exclusive distribution arrangements.
Collective boycotts.
Restrictions on manufacturers appointing alternative distributors.
Section 4 – Abuse of dominant position
Prohibits abuse of a dominant position by an enterprise or group.
Relevant conduct includes:
Unfair or discriminatory distribution conditions.
Predatory pricing.
Denial of market access.
Limiting supply or technical development.
Imposing supplementary contractual obligations.
Section 5 and Section 6 – Combinations
These provisions regulate mergers, acquisitions and amalgamations that may adversely affect competition.
A merger between competing medical distribution platforms may raise concerns involving supplier concentration, data consolidation, network effects and foreclosure of smaller competitors.
B. European Union
The principal provisions are:
Article 101 TFEU – Anti-competitive agreements.
Article 102 TFEU – Abuse of dominant position.
EU Merger Regulation – Anti-competitive concentrations.
C. United States
The principal provisions are:
Sherman Act, Section 1 – Agreements in restraint of trade.
Sherman Act, Section 2 – Monopolisation and attempted monopolisation.
Clayton Act, Section 7 – Anti-competitive mergers and acquisitions.
Federal Trade Commission Act, Section 5 – Unfair methods of competition.
4. Major Forms of Anti-Competitive Conduct
4.1 Exclusive Distribution Agreements
Exclusive distribution agreements arise when a platform requires manufacturers or pharmaceutical suppliers to distribute products exclusively through its system.
Such agreements may restrict competing platforms from obtaining access to essential medicines.
Potential anti-competitive effects:
Foreclosure of competing distribution platforms.
Reduced choice for pharmacies and hospitals.
Increased dependence on a single distributor.
Higher wholesale and retail prices.
Reduced incentives for new platforms to enter the market.
Example: A dominant medical procurement platform enters agreements with all major pharmaceutical manufacturers requiring them to sell exclusively through its marketplace.
The arrangement may violate competition law where it substantially forecloses competing distribution channels without sufficient efficiency justification.
4.2 Predatory Pricing and Below-Cost Distribution
A dominant platform may deliberately sell medicines or medical devices below an appropriate measure of cost to eliminate competing distributors.
The platform may initially provide:
Zero-commission transactions.
Free delivery.
Subsidised pharmaceutical procurement.
Extremely high discounts.
Free inventory management software.
After eliminating competitors, the platform may increase commissions, impose additional fees or reduce supplier discounts.
Competition authorities should distinguish exclusionary predatory pricing from legitimate introductory discounts and efficiency-based price competition.
4.3 Platform Self-Preferencing
Self-preferencing occurs when a medical distribution platform gives preferential treatment to its own pharmaceutical products, affiliated pharmacies or integrated logistics businesses.
Examples include:
Placing affiliated pharmacies at the top of search results.
Giving proprietary medical products preferential visibility.
Providing better delivery terms to affiliated suppliers.
Restricting rival pharmacies from accessing promotional opportunities.
Giving affiliated distributors privileged access to inventory information.
The practice becomes problematic when a dominant platform uses control over marketplace infrastructure to disadvantage independent competitors.
4.4 Discriminatory Access to Distribution Infrastructure
Medical distribution platforms may control commercially important infrastructure such as:
Pharmaceutical inventory databases.
Prescription-processing systems.
Hospital procurement networks.
Medical product authentication systems.
Cold-chain transportation infrastructure.
Digital ordering and fulfilment interfaces.
Discriminatory access may involve charging independent suppliers higher fees, delaying their orders or refusing to provide essential interoperability.
A competition authority must examine whether the infrastructure is commercially indispensable, whether alternative channels exist and whether the refusal has exclusionary effects.
4.5 Price Fixing and Distributor Coordination
Competing pharmaceutical distributors may coordinate their commercial decisions through trade associations or digital platforms.
Potential practices include:
Fixing wholesale margins.
Coordinating discounts.
Agreeing minimum resale prices.
Allocating geographical territories.
Restricting the number of authorised distributors.
Coordinating refusals to supply particular pharmacies.
Digital platforms may facilitate coordination by providing competitors with real-time information concerning prices, inventory and customer demand.
The exchange of commercially sensitive information can create conditions for collusion, although information exchange alone does not automatically establish an infringement.
4.6 Algorithmic Price Manipulation
Medical distribution platforms increasingly use algorithms to determine prices, discounts and commissions.
Anti-competitive risks include:
Algorithms facilitating coordination between competing distributors.
Automated price adjustments that implement an underlying cartel arrangement.
Discriminatory pricing between pharmacies.
Artificially inflated prices during medicine shortages.
Coordinated minimum-price recommendations.
The legal analysis must establish whether the conduct amounts to an agreement, concerted practice or unilateral abuse, depending on the applicable jurisdiction.
4.7 Bundling and Tying
A dominant platform may require hospitals or pharmacies to purchase multiple services together.
For example, a hospital seeking access to a pharmaceutical procurement platform may be required to purchase:
Inventory-management software.
Payment-processing services.
Delivery and cold-chain services.
Medical equipment.
Prescription-management subscriptions.
Bundling can generate efficiencies, but compulsory tying may restrict competitors in adjacent markets.
4.8 Data Exclusivity and Information Foreclosure
Medical distribution platforms collect commercially valuable information, including:
Medicine purchasing patterns.
Supplier pricing information.
Hospital procurement volumes.
Pharmacy inventory levels.
Product demand forecasts.
Delivery and fulfilment information.
A dominant platform may use this information to disadvantage suppliers or rival distributors.
For example, it may use confidential purchasing data to introduce competing private-label products or provide affiliated pharmacies with superior commercial terms.
4.9 Refusal to Deal and Supply Restrictions
A dominant distributor may refuse to supply competing pharmacies or prevent manufacturers from dealing with rival platforms.
This can be particularly serious where the products are essential medicines or specialised medical devices with limited alternative supply channels.
However, legitimate concerns involving product safety, licensing, payment defaults and pharmaceutical regulation must also be considered.
4.10 Anti-Competitive Mergers and Acquisitions
Consolidation between medical distribution platforms may eliminate important competitive constraints.
Competition authorities should examine:
Horizontal overlaps between platforms.
Vertical integration with manufacturers.
Control over pharmaceutical wholesalers.
Access to commercially sensitive data.
Network effects and switching costs.
Potential foreclosure of rival suppliers.
Acquisition of emerging competitors.
5. Important Case Laws and Judicial Decisions
The following cases provide important principles for analysing pharmaceutical distribution, digital healthcare networks, exclusivity, access restrictions and platform monopolisation. Some concern conventional distribution rather than modern online marketplaces, but their principles are directly relevant by analogy.
1. FTC v. Cardinal Health, Inc. (1998)
Federal Trade Commission v. Cardinal Health, Inc., 12 F. Supp. 2d 34 (D.D.C. 1998).
Legal principle: Pharmaceutical distribution market definition and competition.
The case concerned the proposed mergers of major pharmaceutical wholesalers, Cardinal Health and McKesson with other wholesale distributors.
The FTC argued that consolidation would substantially reduce competition in pharmaceutical wholesale distribution. The court examined whether wholesale pharmaceutical distribution constituted a distinct relevant product market and considered the competitive significance of alternative distribution channels, including direct purchasing and self-distribution.
Importance:
Relevant market definition in medical distribution.
Competitive effects of wholesale consolidation.
Importance of alternative distribution channels.
Market concentration and barriers to entry.
The decision demonstrates that pharmaceutical distribution must be analysed according to actual commercial substitution rather than merely the broader healthcare market.
US Federal Trade Commission Logo PNG Transparent & SVG Vector - Freebie Supply
2. FTC v. Cardinal Health, Inc. (2015)
FTC v. Cardinal Health, Case No. 15-cv-3031 (D.D.C. 2015).
Legal principle: Exclusive access to essential pharmaceutical inputs.
The FTC challenged Cardinal Health's conduct in obtaining de facto exclusive distribution rights for heart perfusion agents from the only two manufacturers in 25 local markets.
The FTC alleged that these arrangements prevented potential radiopharmacy competitors from entering the relevant markets.
The matter was resolved through a stipulated permanent injunction, disgorgement of $26.8 million and measures designed to facilitate competition.
Importance:
Exclusive distribution rights can foreclose competitors.
Access to essential medical products can determine market entry.
Vertical agreements may protect downstream market power.
Distribution exclusivity must be assessed for its competitive effects.
This is particularly relevant where a dominant medical distribution platform controls access to products that rival platforms cannot reasonably obtain elsewhere.
June 30, 2021+1
3. FTC v. Surescripts, LLC (2019–2023)
FTC v. Surescripts, LLC, No. 1:19-cv-01080 (D.D.C.).
Legal principle: Digital healthcare platform monopolisation and exclusivity.
Surescripts operated electronic prescription routing and prescription-benefit eligibility networks.
The FTC alleged that the company used exclusionary agreements, loyalty arrangements, threats and other restrictions to prevent customers on both sides of its networks from using competing services.
In March 2023, the court granted the FTC partial summary judgment. The case was subsequently resolved through an approved settlement order in August 2023.
Importance:
Digital healthcare network effects.
Restrictions on multi-homing.
Exclusivity and loyalty arrangements.
Foreclosure of competing healthcare technology platforms.
Importance of interoperability and customer choice.
This is one of the most directly relevant precedents for digital medical distribution and prescription-processing platforms.
Federal Trade Commission+1
Criminal Justice | Lipscomb University
4. FTC v. Vyera Pharmaceuticals, LLC (2020)
Federal Trade Commission v. Vyera Pharmaceuticals LLC, No. 1:20-cv-00706 (S.D.N.Y. 2020).
Legal principle: Restricted pharmaceutical distribution and exclusion of generic competitors.
The FTC and New York authorities challenged the conduct of Vyera Pharmaceuticals concerning Daraprim.
The complaint alleged that Vyera used restricted distribution arrangements, exclusive supply contracts and data-blocking agreements to prevent generic competitors from obtaining sufficient quantities of the branded medicine for bioequivalence testing.
The court allowed important antitrust claims concerning the alleged restrictions to proceed.
Importance:
Restricted distribution systems can impede generic competition.
Exclusive supply arrangements may create entry barriers.
Access to pharmaceutical products is important for regulatory testing.
Control over distribution can be used to protect market power.
The decision illustrates how distribution arrangements can interfere with competition even where the immediate restriction concerns access to products rather than retail prices.
FindLaw
CCI Approves Adani Infra’s Stake Acquisition in PSP Projects
5. Santuka Associates Pvt. Ltd. v. All India Organization of Chemists and Druggists (2012)
Competition Commission of India, Case No. 20 of 2011.
Legal principle: Collective restrictions on pharmaceutical distribution.
The dispute concerned alleged restrictions imposed by pharmaceutical trade associations on the appointment of stockists and the distribution of medicines.
The proceedings examined the role of the All India Organization of Chemists and Druggists and associated organisations in imposing conditions on manufacturers and distributors.
Importance:
Trade association restrictions may violate Section 3.
No-objection certificate requirements can restrict market entry.
Manufacturers must retain commercial freedom to appoint distributors.
Collective pressure and boycotts may restrict competition.
The principles apply to digital medical platforms where supplier associations collectively prevent manufacturers from listing products on competing platforms.
CCI Clears 360 ONE & Claypond Capital's Acquisition in API Holdings
6. Varca Chemists and Druggists v. Chemists and Druggists Association, Goa (2012)
Competition Commission of India, MRTP Case No. C-127/2009/DGIR.
Legal principle: Restrictions on pharmaceutical stockist appointments.
The proceedings concerned the conduct of pharmaceutical trade associations and restrictions affecting the appointment and functioning of medicine distributors.
The relevant competition concerns included collective restrictions on manufacturers, distributor appointment conditions and the use of association influence to regulate market access.
Importance:
Associations cannot substitute collective approval for independent commercial decisions.
Restrictions on distributor appointments may harm competition.
Collective boycotts may prevent new entrants from accessing markets.
Distribution networks must remain open to lawful competition.
Former IPS officer, lawyer among 3 new CCI members - The Economic Times
7. Competition Commission of India v. Coordination Committee of Artists and Technicians of West Bengal (2017)
Supreme Court of India, Civil Appeal No. 6691 of 2014, decided 7 March 2017.
Legal principle: Collective boycott and anti-competitive association conduct.
The Supreme Court examined the application of competition law to collective conduct by associations and the competitive effects of concerted restrictions.
Although the dispute concerned the entertainment industry rather than pharmaceutical distribution, the Court's treatment of collective conduct is relevant to medical distribution associations and coordinated platform restrictions.
Importance:
Collective decisions can constitute anti-competitive agreements.
Industry associations are subject to competition scrutiny.
Boycotts and coordinated restrictions can affect market access.
The substance and economic effects of conduct matter more than its organisational form.
ESM and MuniFin enter euro market as green EU debut nears
8. European Commission – Pharmaceutical Parallel Trade and Distribution Restrictions
AstraZeneca AB v. Commission, Case C-457/10 P (2012).
Legal principle: Abuse of dominance and pharmaceutical market access.
The Court of Justice examined AstraZeneca's conduct involving regulatory procedures and the withdrawal of marketing authorisations, which formed part of the Commission's findings of abuse of dominance.
Although not a digital distribution-platform case, it provides an important example of how regulatory and distribution-related strategies may affect pharmaceutical competition.
Importance:
Dominant pharmaceutical businesses are subject to Article 102 TFEU.
Regulatory procedures cannot be manipulated abusively to exclude competitors.
Competition analysis considers the strategy and its exclusionary effects.
Protection of competitive market access is important in pharmaceutical markets.
6. Indian Pharmaceutical Distribution Competition Decisions
India provides particularly important examples of competition concerns involving pharmaceutical distributors and trade associations.
A. All India Organization of Chemists and Druggists (AIOCD)
The AIOCD-related proceedings are significant because they concern collective restrictions within the pharmaceutical distribution chain.
The competition issues included:
No-objection certificates for appointment of stockists.
Restrictions on the appointment of new distributors.
Collective control over medicine distribution.
Restrictions on manufacturers launching new products.
Boycotts and coordinated commercial pressure.
The central competition-law principle is that trade associations cannot use collective influence to restrict independent commercial decisions of manufacturers and distributors.
B. Coopharma – Cooperativa de Farmacias Puertorriqueñas (2012)
FTC, In re Cooperativa de Farmacias Puertorriqueñas, Docket No. C-4374.
This matter concerned a cooperative of pharmacy owners that allegedly coordinated reimbursement negotiations with insurers and pharmacy benefit managers.
The FTC's final order prohibited the cooperative from facilitating collective price negotiations, refusals to deal and exchanges of competitively sensitive information between competing pharmacies.
Relevance to medical distribution platforms: A digital marketplace cannot become a mechanism through which independent pharmacies collectively determine reimbursement rates, supplier prices or commercial conditions.
C. FTC v. Cardinal Health – 2015
This separate enforcement action demonstrates how control over access to essential pharmaceutical products can create barriers to entry in local distribution markets.
The final settlement included disgorgement and restrictions intended to restore competition. It illustrates the importance of examining control over upstream supply when investigating downstream distribution-platform dominance.
7. Competition Assessment: How Authorities Should Examine Medical Distribution Platforms
Competition authorities should follow a structured assessment.
A. Relevant Market Definition
The first question is whether the relevant market concerns:
Online pharmaceutical distribution.
Offline pharmaceutical wholesale distribution.
E-pharmacy marketplaces.
Hospital procurement platforms.
Medical-device distribution.
Integrated healthcare procurement services.
The relevant market should be determined by examining demand-side and supply-side substitution.
For example, a hospital purchasing specialised diagnostic equipment may not consider an ordinary online pharmacy an effective substitute.
B. Market Power Assessment
Market power should not be determined solely by transaction volume.
Authorities should consider:
Market share.
Number of participating pharmacies.
Manufacturer dependence.
Supplier switching costs.
Network effects.
Access to essential inventory.
Control over prescription-processing infrastructure.
Availability of alternative distribution channels.
Control over relevant commercial data.
C. Network Effects
Medical distribution platforms benefit from cross-side network effects.
For example:
More manufacturers attract more pharmacies.
More pharmacies attract more hospitals and consumers.
More transactions generate better demand forecasting.
Better demand forecasting attracts additional manufacturers.
This creates a self-reinforcing competitive advantage.
However, when a dominant platform prevents participants from using rival platforms, network effects can become a mechanism of exclusion.
D. Foreclosure Analysis
The authority should investigate whether the challenged conduct prevents rival platforms from achieving commercially viable scale.
Relevant questions include:
Can competing platforms obtain medicines from manufacturers?
Can pharmacies use multiple platforms?
Are suppliers contractually restricted from dealing with competitors?
Are platform commissions commercially discriminatory?
Can new entrants access delivery and fulfilment networks?
Does the platform control commercially indispensable information?
E. Objective Justification
Not every restriction is anti-competitive.
Medical distribution requires legitimate controls concerning:
Drug safety.
Storage and temperature requirements.
Counterfeit medicine prevention.
Licensing and regulatory compliance.
Product traceability.
Prescription verification.
Patient confidentiality.
A platform may legitimately impose quality and safety requirements, provided they are proportionate, transparent and not used as a pretext for excluding competitors.
8. Illustrative Hypothetical Case Study
Facts:
Assume that MediSupply is a dominant digital medical distribution platform operating across several Indian states.
It connects pharmaceutical manufacturers, hospitals, independent pharmacies and medical-device suppliers.
The platform introduces the following practices:
Manufacturers must agree not to supply competing platforms.
Independent pharmacies must pay higher commissions than affiliated pharmacies.
Rival platforms are denied access to inventory information.
Hospitals must purchase logistics and inventory software together with medicines.
The platform offers below-cost delivery services to eliminate smaller competitors.
Suppliers are discouraged from listing their products on competing marketplaces.
Competition-law analysis
| Conduct | Potential legal issue |
|---|---|
| Exclusive supply agreements | Section 3 and potentially Section 4 |
| Discriminatory commissions | Section 4 |
| Denial of inventory access | Section 4 |
| Compulsory bundling | Sections 3 and 4 |
| Predatory pricing | Section 4 |
| Supplier foreclosure | Sections 3 and 4 |
The Competition Commission of India would need to establish the relevant market, assess dominance where Section 4 is invoked, examine the competitive effects of each practice and consider any legitimate efficiency or regulatory justification.
Possible outcome: If the evidence establishes an appreciable adverse effect on competition or abuse of dominance, the Commission may impose appropriate remedies under the Competition Act, 2002.
9. Enforcement Challenges
Medical distribution platforms create several challenges for competition authorities.
| Challenge | Competition concern |
|---|---|
| Algorithmic opacity | Difficulties identifying coordinated pricing |
| Data concentration | Strategic advantages over competitors |
| Multi-sided markets | Complex market definition |
| Network effects | Entrenchment of platform dominance |
| Vertical integration | Potential discriminatory treatment |
| Healthcare regulation | Distinguishing safety requirements from exclusion |
| Cross-border distribution | Jurisdictional and enforcement difficulties |
| Emergency shortages | Risk of exploitative or exclusionary conduct |
An additional challenge is the relationship between competition law and pharmaceutical regulation. Competition authorities must ensure that enforcement does not undermine legitimate medicine-quality, licensing and patient-protection requirements.
10. Remedies and Corrective Measures
Competition authorities may consider the following remedies where an infringement is established.
A. Structural remedies
Divestiture of overlapping distribution businesses.
Separation of competing platform operations.
Removal of structural barriers to entry.
B. Behavioural remedies
Prohibition of unjustified exclusivity agreements.
Non-discriminatory access to platform infrastructure.
Transparent supplier commission policies.
Prohibition of anti-competitive tying and bundling.
Freedom for pharmacies to use competing platforms.
Restrictions on misuse of confidential supplier data.
C. Digital competition remedies
Interoperability between prescription and procurement systems.
Data portability where legally permissible.
Transparent ranking and recommendation systems.
Independent algorithmic audits.
Fair access to digital inventory interfaces.
D. Consumer and patient protection
Greater medicine price transparency.
Protection against discriminatory medicine pricing.
Reliable medicine availability.
Measures preventing artificial supply restrictions.
Safeguards for patient and prescription data.
11. Critical Legal Principles Emerging from the Case Laws
The eight decisions discussed above demonstrate several important principles:
Pharmaceutical distribution is a distinct area of competition analysis requiring careful market definition.
Exclusive distribution agreements can prevent competitors from obtaining access to essential products.
Digital healthcare networks can use exclusivity and loyalty arrangements to restrict multi-homing.
Restricted pharmaceutical distribution can obstruct generic entry.
Trade associations cannot collectively restrict independent distributor appointments.
Collective price negotiations and boycotts may violate competition law.
Dominant pharmaceutical enterprises cannot abuse regulatory or commercial mechanisms to exclude competitors.
Competition authorities must distinguish legitimate healthcare efficiencies from exclusionary restrictions.
Important distinction concerning the Cardinal cases: The 1998 merger decision rejected the FTC's challenge because the court found the proposed market definition and likely competitive harm insufficiently established. The separate 2015 Cardinal enforcement matter resulted in a settlement concerning exclusive access to essential radiopharmaceutical inputs. They should not be treated as the same proceeding.
12. Conclusion
Medical distribution platforms are becoming essential components of modern healthcare infrastructure. Their ability to connect manufacturers, wholesalers, pharmacies, hospitals and patients creates substantial economic efficiencies but also creates opportunities for market foreclosure and exploitation.
The most significant competition concerns involve exclusive distribution, discriminatory access, algorithmic pricing, predatory pricing, supplier coordination, data concentration, self-preferencing and anti-competitive mergers.
Competition law must therefore protect the openness and contestability of medical distribution markets while respecting legitimate pharmaceutical safety and regulatory obligations.
In India, Sections 3 and 4 of the Competition Act, 2002 provide the principal framework for addressing these concerns. International decisions involving Cardinal Health, Surescripts and Vyera Pharmaceuticals offer useful comparative guidance.
Ultimately, the objective is not merely to increase the number of medical distribution platforms, but to ensure that manufacturers, pharmacies, hospitals and patients retain meaningful access to competitive, transparent and reliable distribution channels.

comments